<DOC>
	<DOCNO>NCT02563496</DOCNO>
	<brief_summary>This prospective , open-label , multicenter , non-comparative , single arm study pediatric subject Plasmodium vivax ( P. vivax ) malaria , age 6 month &lt; 16 year age . A total 60 subject enrol . Potential subject slide-positive P. vivax start site chloroquine ( CQ ) per local/national guideline . Sites 48 hour obtain consent . Once full consent provide , subject screen , eligible , receive Tafenoquine ( TQ ) , give single dose Day 1 . All study medication take food . After treatment period , subject attend 7 follow-up visit Day 120 ( Days 3 , 8 , 15 , 29 , 60 , 90 120 ) . The main cohort consist subject age &gt; =2 year &lt; 16 year restriction gender . Subjects dose accord four weight band . Within total 60 enrol pediatric subject , second cohort 6 infant age &gt; =6 month &lt; 2 year ( weigh &gt; =5 kilogram [ kg ] ) recruit follow completion plan first interim analysis . An interim analysis conduct sufficient data 16 subject available assess pharmacokinetic ( PK ) safety parameter . If need , second interim analysis conduct total 32 subject enrol . The primary objective PK bridging study adequately characterize systemic TQ exposure pediatric population .</brief_summary>
	<brief_title>A Pharmacokinetics , Safety Efficacy Study Tafenoquine ( TQ ) Pediatric Subjects With Plasmodium Vivax ( P. Vivax ) Malaria</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Vivax</mesh_term>
	<mesh_term>Chloroquine</mesh_term>
	<mesh_term>Chloroquine diphosphate</mesh_term>
	<mesh_term>Tafenoquine</mesh_term>
	<criteria>Subject &gt; =2 year &lt; 16 year age time sign assent and/or inform consent . An additional cohort subject age &gt; =6 month &lt; 2 year may recruit follow first interim analysis . The subject positive malarial smear P. vivax . The subject history fever within 48 hour prior enrollment . The subject glucose 6phosphate dehydrogenase ( G6PD ) value ( measure quantitative spectrophotometric phenotype assay ) &gt; =70 % site median value G6PD normal adult male . The subject screening Hb value &gt; =8 gram per decilitre ( g/dL ) . The subject body weight &gt; =5 kg . Males female eligible enter study . A female eligible enter participate study nonpregnant , nonlactating : Nonchildbearing potential ( i.e. , premenstrual ) ; Childbearing potential , negative pregnancy test screening , agree comply one follow treatment stage study period 90 day stop study medication : Complete abstinence intercourse 2 week prior administration study medication , throughout study period 90 day stop study medication ; Use combine oral contraceptive consist spermicide either condom diaphragm ; Use intrauterine device document failure rate &lt; 1 % per year ; Use depo provera injection ; Male partner sterile prior female subject 's entry study sole sexual partner female . The subject and/or subject 's parent ( ) /legal guardian ( ) agree G6PD genotyping context subsequent hemolytic anemia AE . The subject parent ( ) /legal guardian ( ) willing able comply study protocol . In accordance regional/local law regulation , parent ( ) /legal guardian ( ) give write inform , dated consent ; subject give write assent , applicable , participate study . The subject mixed malaria infection ( identify malarial smear rapid diagnostic test ) . The subject condition may affect absorption study medication , severe vomiting ( food inability take food previous 8 hour ) . The subject liver alanine aminotransferase ( ALT ) &gt; 2 time upper limit normal ( ULN ) . The subject clinically significant concurrent illness ( example ; pneumonia , meningitis , septicaemia , coagulopathy , severe hemorrhage ) , preexist condition ( e.g. , renal disease , malignancy , malnutrition , know preexist human immunodeficiency virus [ HIV ] ) , febrile convulsion prior consent , clinical sign symptom severe cardiovascular disease ( example ; congenital heart disease ) . The subject history porphyria , psoriasis , epilepsy . The subject take antimalarial ( example ; artemisininbased combination therapy , mefloquine , primaquine , 4 8aminoquinoline ) drug antimalarial activity within 30 day prior study entry . The subject receive treatment investigational drug within 30 day study entry , within 5 halflives , whichever longer . The subject take likely require study use : histamine2 blocker , antacid , antidiabetic drug biguanide class ( i.e. , phenformin , buformin ) , antiarrhythmic agent dofetilide , procainamide , pilsicainide . The subject serum creatinine ULN currently take metformin . The subject history allergy intolerance chloroquine , mefloquine , tafenoquine , primaquine , 4 8aminoquinoline . The subject previously enrol study . The subject severe P. vivax malaria define world health organization ( WHO ) criterion</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>pharmacokinetic</keyword>
	<keyword>pediatric</keyword>
	<keyword>Tafenoquine</keyword>
	<keyword>Plasmodium vivax Malaria</keyword>
	<keyword>G6PD deficiency</keyword>
</DOC>